Kornimate/medical-research-clean huggingface dataset:
fascial therapy in elbow hemophilic arthropathy

Conditions: Hemophilia

Summary: introduction: the common clinical manifestations of hemophilia are skeletal muscle bleeds, especially hematomas and hemarthrosis. repeated episodes of joint bleeding in certain joints, causing a progressive joint deterioration. secondary disorders to this joint degeneration include: biomechanical alterations, loss of range of movement and periarticular muscle atrophy. design. a prospective, multicenter and longitudinal pilot study to evaluate the efficacy of a treatment protocol with fascial therapy applied in patients with hemophilic arthropathy of the elbow. aimed: to evaluate the safety and efficacy of a physiotherapy treatment by fascial therapy in patients with hemophilic arthropathy of the elbow patients: a total of 60 patients with hemophilia and prophylactic treatment will be recruited for inclusion in the study. patients will be recruited in 6 centers, from different regions of spain. intervention: each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. the treatment program includes 11 maneuvers that must be administered bilaterally: measuring instruments and study variables: goniometric evaluation (range of movement); visual analog scale (joint pain); haemophilia joint health score (joint status); dash questionnaire (functionality of upper limbs); sf-36 questionnaire (perception of quality of life). at the same time, the study will allow to determine joint bleeding caused by applied physiotherapy treatment. expected results: first, it is intended to demonstrate the safety of this physiotherapy technique in patients with hemophilia. likewise, an improvement in the perception of elbow pain and joint mobility is expected. an improved functionality of the upper limb is also foreseen and with it, an enhanced perception of quality of life of these patients.


Eligibility criteria:
inclusion criteria: * patients diagnosed with hemophilia a and b * patients adults (over 18 years) * patients diagnosed with hemophilic arthropathy of the elbow (by clinical assessment with the hemophilia joint health score) * patients pn prophylactic treatment with fviii / fix concentrates. exclusion criteria: * patients without ambulation ability * patients with inhibitors * patients with neurological or cognitive alterations that impede the comprehension of the questionnaires and physical tests * patients who have not signed the informed consent document.

Keywords: hemophilia elbow arthropathy joint pain range of motion myofascial techniques safety patients quality of life functionality
evaluation of routine follow-up coronary angiography after percutaneous coronary intervention trial

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to evaluate the long term clinical impact of routine follow-up coronary angiography after percutaneous coronary intervention (pci). the primary endpoint is a composite of death/myocardial infarction/stroke/emergency hospitalization for acute coronary syndrome/hospitalization for congestive heart failure at 3-year after percutaneous coronary intervention.

routine follow-up coronary angiography after percutaneous coronary intervention has been performed to detect restenosis in a lot of pci centers in japan. on the other hand, previous studies reported that routine follow-up coronary angiography might lead to unnecessary reinterventions in asymptomatic patients. in this situation, the effect of routine follow-up coronary angiography on long-term clinical outcomes remains unknown. the purpose of this study is to evaluate the long-term clinical impact of routine follow-up coronary angiography after pci compared with clinical follow-up alone. the primary endpoint of this study is a composite of death/myocardial infarction/stroke/emergency hospitalization for acute coronary syndrome/hospitalization for congestive heart failure at three-year after percutaneous coronary intervention. the design of this study is almost all-comer design enrolling patients received pci without any exclusion criteria.

Eligibility criteria:
inclusion criteria: * patients received percutaneous coronary intervention * patients older than 20 years old * patients who will not scheduled any staged percutaneous coronary intervention

Keywords: follow-up coronary angiography
intestinal microbiota and thyroid cancer

Conditions: Microbiota

Summary: thyroid cancer (tc), the most common malignancy of the endocrine system, is currently the fifth most common malignancy diagnosed in women (1). the incidence of tc in the united states has increased by an average of 3% per year over the past 4 decades. much progress has been made in exploring the etiology and pathogenesis of thyroid cancer, while the exact etiology remains unknown, tc is thought to arise from interactions between genetic susceptibility factors, epigenetic effects, and various environmental factors. besides the improvement of diagnosis, tc increasing incidence emphasize that other important factors such as the environment play an important role in disease pathogenesis. while microbiota as an environment factor to some cancers accept widespread attention, if microbiota also as a risk factor for tc, it is worthy to be considered.

thyroid cancer (tc), the most common malignancy of the endocrine system, is currently the fifth most common malignancy diagnosed in women (1). the incidence of tc in the united states has increased by an average of 3% per year over the past 4 decades. according to the china national cancer registry data in 2015 (3), there were estimated 90,000 new tc cases in china, and its incidence has risen sharply. much progress has been made in exploring the etiology and pathogenesis of thyroid cancer, while the exact etiology remains unknown, tc is thought to arise from interactions between genetic susceptibility factors, epigenetic effects, and various environmental factors. besides the improvement of diagnosis, tc increasing incidence emphasize that other important factors such as the environment play an important role in disease pathogenesis. while microbiota as an environment factor to some cancers accept widespread attention, if microbiota also as a risk factor for tc, it is worthy to be considered.

Eligibility criteria:
inclusion criteria: * aged 18 to 65 years * patients of thyroid cancer exclusion criteria: * pregnancy * lactation * cigarette smoking * alcohol addiction * hypertension * diabetes mellitus * lipid dysregulation * bmi \> 27 * recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or chinese herbal medicine * history of disease with an autoimmune component, such as ms, rheumatoid arthritis, ibs, or ibd * history of malignancy or any gastrointestinal tract surgery

Keywords: gut microbiota 16s rrna gene thyroid cancer metabonomics
long-term management of patients with ruptured hcc

Conditions: Hepatocellular Carcinoma

Summary: the main objective of this work is to evaluate the prevalence and results of specific management of hcc after spontaneous rupture, since the arrival of sorafenib in 2008.

retrospective, observational, multicenter study over the period from january 2008 to april 2024. cases had to be 18 years or older. they were identified by two different methodologies adapted to the 4 participating centers. in particular, a request for icd10 c22.0 (chc) codes associated with k66.1 (hemoperitoneum) was carried out by the medical information departments (dim) of the caen university hospital and the avicenne hospital. secondly, the automated keyword selection tools "cohort 360" and "i2b2" were used at the la pitié salpetrière and paul brousse hospital centers to identify the terms "chc" and "ruptured" in the computerized patient files. secondarily, duplicates and coding errors were excluded.

Eligibility criteria:
inclusion criteria: * ruptured hepatocellular carcinoma with or without cirrhosis exclusion criteria: * liver adenoma without histologically proven hcc * other benign or malignant liver tumors * atcd of potentially triggering interventional procedure in the previous month. * hemorrhagic ascites without tumor * intratumoral hemorrhages without hemoperitoneum or capsular rupture
hypofractionated stereotactic linear accelerator radiotherapy of uveal melanoma

Conditions: Uveal Melanoma

Summary: the purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic linac radiotherapy with 10 fractions at 6 gy per fraction at the 80% isodose for the planning target volume (ptv) in patients with uveal melanoma. patients will be followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity, secondary complications and survival.


Eligibility criteria:
inclusion criteria: * the initial height of the melanoma is 7 mm or higher. * juxtapapillary and/or juxtamacular melanomas with a height of 3 mm or higher and if the central tumor distance to the optic disc and/or the macula is 3 mm or less. * if other forms of conservative treatment of the melanoma are not possible. exclusion criteria: * prior/concomitant treatment. * extrascleral tumor extension is present. * if the presence of neovascular glaucoma is detected before treatment. * if metastasis is detected at baseline. * previous participation in any study of investigational drugs within 3 month preceding day 0. * pregnant women are not allowed to participate in the study.
cardiac mri for optimal heart failure outcomes with crt upgrades

Conditions: Chronic Systolic Heart Failure; Paroxysmal VT

Summary: this study will investigate the use of cardiac mri in patients with standard icds and pacemakers to inform how cardiac resynchronization therapy (crt) can best be implemented in these patient and which patients are the best candidates for crt.

the scientific premise of this proposal is that left and right ventricular (lv and rv) structural characteristics in patients with existing cardiac implantable electronic devices and heart failure who may benefit from an upgrade to a cardiac resynchronization therapy (crt) device can be assessed very effectively using cardiac mri using sequences designed for post-device imaging. furthermore, a comparative analysis of the differences in lv/rv structural characteristics in patients with existing devices referred for crt upgrades versus those with de novo crt implants is expected to be very useful for developing effective strategies for optimal patient selection for crt upgrades and implementation of crt upgrades in appropriate patients. patient selection for crt upgrades is very important considering that complication rates are higher than in de novo crt procedures and nonresponse rates are still high. with this in mind, we are performing a study of 100 patients, including 50 prospectively enrolled patients with lvef less than or equal to 0.35 and new york heart association class ii-iii heart failure, who will be compared with an existing cohort of 50 patients with recent de novo crt implants, pre-crt mris, and response data. the 50 prospectively enrolled patients having crt upgrades will undergo a pre-crt cardiac mri, pre-crt/post-crt echocardiography, and pre-crt/post-crt cardiopulmonary exercise testing. in the first aim, we will assess differences in cardiac mri findings between crt upgrade patients and de novo crt patients. in the second aim, we will assess the impact of cardiac mri findings on lv reverse remodeling and cardiopulmonary capacity in the two groups. in summary, we propose a comprehensive prospective crt/mri study in crt upgrade patients with comparison to a complete mri dataset of patients with de novo crt implants in order to identify key differences in mri findings in these cohorts and the impact of these mri-based scar and activation findings on clinical outcomes. we expect that our results will have a significant public health impact for patients with heart failure referred for crt upgrades.

Eligibility criteria:
inclusion criteria: - undergoing upgrade from an existing pacemaker or icd to a crt device. exclusion criteria: * inability to provide informed consent * pregnancy * presence of metal embedded in the body due to prior accident or injury, as documented by skull films or other imaging * cerebral aneurysm clips * cochlear implants * other metallic implants known to be contraindications to mri (pacemakers and icds are allowed) * severe claustrophobia * acute kidney injury * acute renal failure * gadolinium allergy * abandoned leads
nt-probnp levels in the prediction of intrapartum and postpartum events in adult congenital heart disease patients

Conditions: Congenital Heart Disease; Pregnancy Complications

Summary: the purpose of this study is to determine if nt-bnp levels obtained at time of admission for delivery are predictive of intrapartum or postpartum complications in patients with adult congenital heart disease.

amino-terminal pro-b-type natiuretic peptide (nt-probnp) is a prohormone released from cardiac ventricular myocytes in direct response to cardiac workload. secreted in the biologically inactive form, nt-probnp is cleaved in the circulation into bnp, which subsequently exerts both vasodilatory and diuretic effects. the principal clinical utility of serum nt-probnp measurement has been as an adjunctive marker in the diagnosis of subclinical heart failure, with higher levels typically reflective of increasing cardiac dysfunction. the proposed prospective cohort study intends to collect serum nt-probnp levels in singleton achd patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events. both pregnant patients with previously-diagnosed achd and those diagnosed and delivering during the study interval will be candidates for participation, and a gestational age threshold of 37 weeks will be utilized for the control group.

Eligibility criteria:
inclusion criteria: * pregnant adult women ages 18 - 50 * pregnancy with congenital heart disease (study group) or without congenital heart disease (control group) exclusion criteria: * non-pregnant patients * non-english-speaking patients * maternal age \ 50 years * patients with hypertensive complications of pregnancy * maternal peripartum cardiomyopathy * multiple gestation
taiwan cohort - chronic thromboembolic pulmonary hypertension registry

Conditions: The Geodemographics of CTEPH in Taiwan

Summary: the diagnosis of chronic thromboembolic pulmonary hypertension (cteph) is difficult for numerous reasons and is related with a poor prognosis. in taiwan, the incidence of cteph and its clinical features are unknown. this study aims at evaluating the prevalence, clinical characteristics, and management of cteph in a taiwanese cohort. primary objective: - to investigate the geodemographics of cteph in taiwan secondary objectives: * to characterize the demographics and clinical presentation of patients with cteph * to describe the real-world management and treatment outcome of patients with cteph * to identify the risk factors of cteph * to assess the relationship between risk factors/patients' characteristics and clinical outcomes for cteph * to evaluate the prognosis of cteph in taiwan using survival assessment


Eligibility criteria:
inclusion criteria: 1. right heart catheterization (rhc) results that are in line with both of the following haemodynamic levels: mean pulmonary arterial pressure (mpap) ≥ 25 mmhg at rest and pulmonary arterial wedge pressure (pawp) ≤ 15 mmhg 2. confirmation of cteph diagnosis by one of the following as recommended by standard guidelines: at least 1 (segmental) perfusion defect(s) in ventilation-perfusion (v/q) / perfusion scan or pulmonary artery obstruction seen by multidetector computed tomography (mdct) angiography or conventional pulmonary cineangiography. 3. presence of pulmonary hypertension or evidence of pulmonary thromboembolism after at least 3 months of anticoagulation treatment. exclusion criteria: * not written informed consent * not meet inclusion criteria

Keywords: chronic thromboembolic pulmonary hypertension
capstan medical tmvr study: fih

Conditions: Mitral Regurgitation

Summary: this study is a prospective, multi-center, non-randomized first in human study to evaluate the safety and feasibility of the capstan medical tmvr system for intervention in adults with moderate-severe or greater mitral regurgitation who are not surgical candidates.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years at the time of consent. * moderate-severe (3+) or severe (4+) mitral regurgitation * nyha ii or greater symptoms despite optimal medical treatment. * the local multi-disciplinary heart team agrees that tmvr is the preferred treatment over surgical intervention or other available treatment options (such as teer). * ability and willingness to provide written informed consent prior to any study related procedure(s). exclusion criteria: * lvef less than 20% * anatomic features (e.g., annular dimensions, neo-lvot area, transfemoral and transseptal access, excessive mac) unsuitable for the capstan system * severe aortic valve stenosis or regurgitation * severe mitral stenosis * severe right ventricular dysfunction or severe tricuspid valve disease * evidence of intracardiac thrombus, vegetation, or mass * prior mitral valve intervention that would interfere with the appropriate placement of the capstan valve * any percutaneous coronary, carotid, or other endovascular intervention within 30 days prior to procedure * myocardial infarction within 30 days prior to procedure * cardiac resynchronization therapy (crt) device implanted within 30 days of procedure * active endocarditis, other ongoing infection requiring antibiotic therapy * stroke or transient ischemic attack (tia) within 30 days of procedure * active peptic ulcer or active gastrointestinal bleeding * severe pulmonary arterial hypertension with fixed pasp greater than 85mmhg * end-stage renal failure on dialysis * life expectancy less than 1 year * subject is on the waiting list for a heart transplant or has had a prior heart transplant * pregnant (participants of childbearing age are required to have a negative pregnancy test). * known allergy to antiplatelet therapy, heparin, or to device materials * inability to tolerate anticoagulation or antiplatelet therapies * absence of appropriate venous access * unable to have transesophageal echocardiography * unwillingness to complete the required follow-up visits

Keywords: tmvr mitral regurgitation
computed tomography ct venography during postpartum venous thromboembolism

Conditions: Pulmonary Thromboembolism

Summary: the purpose of this study is to determine whether systematically performing computed tomography (ct) venography (i.e a ct acquisition of the pelvis and of the lower limbs, during the venous phase of opacification) in addition to thoracic ct angiography in women with suspected postpartum pulmonary embolism (pe) results in a gain in venous thromboembolism detection rate.

pulmonary embolism (pe) remains a leading cause of maternal death during postpartum in developed countries; thoracic computed tomography angiography (cta) is the first-line diagnostic test for pe suspicion, but has a 20 to 35% rate of inconclusiveness during pregnancy and postpartum, 2 to 3 times higher than that of the general population. ct venography (ctv) consists in a delayed ct acquisition of the abdomen, pelvis and lower limbs, 3 minutes after starting contrast administration. it can be used for detecting deep venous thrombosis (dvt), the source of emboli in most pes. the investigators hypothesized most postpartum pes are due to pelvic vein thrombosis and that detecting such pelvic dvt by performing systematic ctv could increase the overall venous thromboembolism (vte) detection.

Eligibility criteria:
inclusion criteria: * women with clinically suspected pulmonary embolism (pe) during the first 6 weeks postpartum, without any sign of severe pe (shock, hypotension), referred for ct angiography * absence of contraindication to iodinated contrast medium injection (previous allergic reaction to iodinated contrast medium, renal insufficiency with creatine clearance less than 30ml/mn, uncontrolled hyperthyroidism) * age \> 18 years * health insurance * possibility to have 3-month follow-up * obtention of written informed consent (ability to give consent) exclusion criteria: * anticoagulation at therapeutic dosage for another reason than the suspicion of pe for more than 72 hours * new pregnancy (in case of any doubt after medical history review, βhcg blood test must be realized to ensure patient's pregnancy status) * contrast medium extravasation during injection * cta or ctv not performed according to the study requirements
corneal densitometry changes with adenoviral sei

Conditions: Corneal Disease

Summary: adenoviral sub epithelial infiltrates (sei) affect ocular function.they lead to reduced vision, photophobia, glare, halos, and foreign body sensation.

first group of patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.s econd group underwent transepithelial ptk for subepithelial infiltrates. baseline and post-treatment full ophthalmic examination was done.

Eligibility criteria:
inclusion criteria: * adenoviral sei exclusion criteria: * other corneal diseases

Keywords: adenoviral infiltrates ptk tacrolimus
cataract surgery in conjunction with ab-interno canaloplasty compared to cataract surgery only in patients with mild to moderate primary open-angle glaucoma

Conditions: Primary Open Angle Glaucoma

Summary: a prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the itrack advance canaloplasty device (nova eye, inc.) to cataract surgery only in patients with mild to moderate, primary open angle glaucoma. subjects will be followed for 24 months.


Eligibility criteria:
inclusion criteria: * mild to moderate, primary open angle glaucoma * characteristics consistent with mild to moderate glaucoma * use of 1 - 4 ocular hypotensive medications at the screening exam and meets the iop (intraocular pressure) criteria * visually significant cataract exclusion criteria: any of the following prior treatments for glaucoma (study eye): * laser trabeculoplasty * endocyclophotocoagulation (ecp) or micropulse laser * istent or istent inject * hydrus microstent * trabeculectomy or other bleb forming procedure including xen, express, and glaucoma drainage device/valve. * prior canaloplasty (ab-interno and ab-externo) * prior goniotomy, or trabeculotomy (ab-interno or ab-externo) * suprachoroidal stent (e.g., cypass, istent supra, xen, miniject) * concurrent iop-lowering procedure other than use of the itracktm advance canaloplasty device at the time of surgery (e.g., ecp, cpc, etc.) * previous treatment with itrack (note: permitted if fellow eye only was treated) * acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma

Keywords: canaloplasty